KINETA, INC./DE
DelistedCIK 1445283fmd_1PKXYHW415ADCCJ738BW2MJTJHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Mar 31, 2025, 42 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 8 | 5 | 3 | 5 | 7 | 9 | 2 | 5 | 0 |
| Research and development | 23 | 34 | 54 | 50 | 23 | 22 | 16 | 16 | 9 | 5 |
| Total operating expenses | 29 | 46 | 65 | 66 | 30 | 63 | 20 | 43 | 21 | 14 |
| Operating income | (25) | (37) | (60) | (63) | (30) | (56) | (11) | (42) | (16) | (14) |
| Interest expense | 1 | – | – | – | 1 | 2 | 1 | 4 | 0 | (0) |
| Interest and investment income | – | 0 | 1 | 1 | 1 | – | – | – | – | – |
| Other non-operating income (expense) | 0 | (0) | (0) | 0 | (1) | (2) | (1) | (22) | 2 | (4) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (25) | (37) | (59) | (62) | (31) | (57) | (12) | (63) | (14) | (17) |
| Net income to common shareholders | (23) | (39) | (59) | – | (31) | (51) | (40) | – | – | – |